A carregar...
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
Histone deacetylase inhibitors (HDIs) represent a new class of anticancer drugs. Suberoylanilide hydroxamic acid (SAHA), the first HDI approved for the treatment of cutaneous T cell lymphoma (CTCL), is currently being tested in clinical trials for other cancers. However, SAHA has been ineffective ag...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891104/ https://ncbi.nlm.nih.gov/pubmed/26848526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7134 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|